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A B S T R A C T
Aims: Oxidative stress is a driver in the development of type 2 diabetes (T2DM) complications. As thiols (R-SH)
are oxidized by reactive oxygen and sulfur species, circulating concentrations may directly reflect systemic redox
status. We hypothesized that high serum R-SH concentrations are a reflection of a favourable redox status and
may therefore positively associate with disease status.
Methods: R-SH were measured in serum of 943 T2DM outpatients (55% males, 65 years and HbA1c of 6.7%
(50mmol/mol)) with a follow-up period of 1.2 years.
Results: In the highest R-SH tertile patients were younger, more often men, had less microvascular complica-
tions, lower HbA1c and were more often treated nutritionally or with oral glucose-lowering drugs. Age- and sex
adjusted hazard ratios for developing micro-, macro- or any complication plus death were 0.994, 0.992 and
0.993: even after adjustment for potential confounders. The Harrell’s C statistic to predict microvascular com-
plications or any complication plus death was higher in the models with R-SH than in those without R-SH.
Conclusions: Although R-SH concentrations were associated with a favourable disease status, it did not add to the
predictive capacity for long-term complications. Based on the current data R-SH seems unsuitable as a prognostic
marker in T2DM.
Introduction
Hyperglycemia promotes a state of systemic oxidative stress, in
which disproportionate levels of reactive oxygen species (ROS) cause an
increase in insulin resistance and β-cell dysfunction, thereby con-
tributing to the progression of type 2 diabetes mellitus (T2DM) [1,2].
Oxidative stress also plays a key role in the pathogenesis of micro-
vascular and macrovascular complications of diabetes, all of which are
associated with significant morbidity and mortality as well as reduced
quality of life [2–6].
At physiological levels, ROS play essential roles in cell signalling
and homeostasis [7,8]. An elaborate network of endogenous anti-
oxidant mechanisms exists to prevent cellular damage by removing
excess ROS and containing the action radius close to their sites of
production. Oxidative stress results from an imbalance between ROS
production and antioxidant defence capacity favouring the former [9].
Under these conditions, ROS can oxidize and damage cellular macro-
molecules including nucleic acids, lipids and proteins, thereby changing
the properties of the cell membrane and intracellular constituents in-
cluding DNA and enzymes, and affecting cellular function and viability
[3].
Thiols, compounds with a free sulfhydryl (R-SH) moiety, occur in
the form of proteins containing one or more free cysteine groups or low-
molecular-weight compounds (e.g. glutathione) in cells and extra-
cellular fluids. In serum, the concentration of all thiols added together
is lower than that intracellular, with albumin being the most abundant
https://doi.org/10.1016/j.jcte.2019.100182
Received 2 November 2018; Received in revised form 4 February 2019; Accepted 4 February 2019
⁎ Corresponding author at: University of Groningen, University Medical Centre, Department of Internal Medicine. Hanzeplein 1, 9700 RB, HP AA41 Groningen, the
Netherlands.
E-mail address: P.r.van.dijk@umcg.nl (P.R. van Dijk).
1 Contributed equally to this work.
Journal of Clinical & Translational Endocrinology 16 (2019) 100182
2214-6237/ © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
thiol [10]. These R-SH groups are readily oxidized by ROS and other
reactive species. The circulating concentrations of total R-SH has re-
cently been proposed to directly reflect the whole-body redox status: a
decrease in circulating R-SH concentration may reflect an increased
oxidative poise and therefore be indicative of oxidative stress [5,11,12].
High R-SH serum concentrations have previously been shown to also be
associated with a beneficial cardiovascular risk profile and a better
patient and graft survival in renal transplant recipients [13]. This may
indicate its potential usefulness as a low-cost, high-throughput
screening tool for whole-body redox status in translational studies; it
may also be a promising target for intervention. Moreover, in an ex-
ploratory study we demonstrated a favourable association of serum R-
SH with markers of heart failure and disease outcome in non-T2DM
individuals [11]. It has been demonstrated in a small cohort that serum
R-SH are reduced in T2DM patients as compared to healthy adults [14].
Another small study found that R-SH concentrations are lower in T2DM
patients with complications as compared to those without complica-
tions [15]. However, this study lacked relevant clinical data including
glycemic control and the longitudinal relationship between R-SH and
outcomes is still unknown. Nevertheless, these findings suggest that
elevated R-SH concentrations may play a favourable role in the pa-
thophysiology and prognosis of T2DM. Given the antioxidant properties
of R-SH and the possibility of supplementation affecting circulating
thiol concentrations, this may have implications for future therapeutic
interventions [16].
Given the potential of R-SH as a modifiable biomarker of ROS-
Table 1
Baseline patient characteristics expressed as tertiles of serum R-SH concentration.
Overall N= 943 Tertile 1 N=310 Tertile 2 N=315 Tertile 3 N=318 P-value
R-SH, µM 202 ± 48 <181 (149 ± 25) 181–227 (202 ± 13) > 227 (255 ± 21)
Demographics
Age, years 65.0 ± 10.0 66.9 ± 9.6 64.9 ± 10.4 63.4 ± 9.8 <0.001
Diabetes duration, years 6.5 [2.9–10.1] 5.9 [2.9–9.8] 6.4 [2.6–9.8] 6.7 [3.4–10.6] 0.543
Male gender, n (%) 517 (54.7) 142 (45.8) 179 (56.8) 195 (61.3) <0.001
Current smoker, n (%) 158 (16.7) 53 (17.1) 57 (18.1) 48 (15.1) 0.578
BMI, kg/m2 29.3 [26.8–33.0] 29.7 [27.1–33.9] 29.7 [26.8–33.5] 28.7 [26.2–32.0] 0.001
Systolic blood pressure, mm Hg 135.6 [125.0–144.0] 136.0 [128.0–144.0] 134.0 [124.0–145.0] 135.0 [125.0–142.0] 0.488
Diastolic blood pressure, mm Hg 80.0 [71.0–83.0] 80.0 [72.0–84.0] 80.0 [70.0–82.0] 80.0 [70.0–82.0] 0.492
Complications
Microvascular complications, n (%) 275 (29.2) 101 (32.6) 98 (31.1) 76 (23.9) 0.037
Micro-albuminuria, n (%) 117 (12.4) 38 (12.3) 40 (12.7) 39 (12.3) 0.982
Macro-albuminuria, n (%) 11 (1.3) 5 (1.6) 5 (1.6) 2 (0.6) 0.453
Retinopathy, n (%) 38 (4.0) 19 (6.1) 15 (4.8) 4 (1.3) 0.006
Neuropathy, n (%) 175 (18.5) 66 (21.3) 62 (19.7) 47 (14.8) 0.091
Macrovascular complications, n (%) 215 (22.7) 77 (24.8) 65 (20.6) 72 (22.6) 0.589
Angina pectoris, n (%) 81 (8.6) 26 (8.4) 29 (9.2) 26 (8.2) 0.593
Myocardial infarction, n (%) 82 (8.7) 32 (10.3) 26 (8.3) 23 (7.2) 0.330
PTCA, n (%) 50 (5.3) 15 (4.8) 18 (5.7) 17 (5.3) 0.729
CABG, n (%) 45 (4.8) 19 (6.1) 12 (3.8) 14 (4.4) 0.424
TIA, n (%) 29 (3.1) 9 (2.9) 12 (3.8) 8 (2.5) 0.470
CVA, n (%) 38 (4.0) 15 (4.8) 7 (2.2) 16 (5.0) 0.214
Heart failure, n (%) 25 (2.6) 11 (3.5) 10 (3.2) 4 (1.3) 0.115
Laboratory Measurements
HbA1c, % (mmol/mol) 6.7 ± 0.7 (50 ± 9) 6.8 ± 0.9 (51 ± 9) 6.7 ± 0.8 (50 ± 9) 6.5 ± 0.7 (48 ± 8) < 0.001
eGFR (MDRD), ml/min/1.73m2 73.0 [61.0–86.0] 69.0 [60.0–81.0] 73.0 [60.0–86.0] 77.0 [66.0–90.0] 0.528
Total cholesterol, mmol/L 4.3 [3.7–5.0] 4.3 [3.6–4.9] 4.4 [3.7–5.1] 4.2 [3.7–4.8] 0.138
HDL cholesterol, mmol/L 1.2 [1.0–1.5] 1.2 [1.0–1.5] 1.2 [1.0–1.5] 1.3 [1.1–1.5] 0.158
Total cholesterol:HDL ratio 3.4 [2.8–4.2] 3.3 [2.8–4.3] 3.6 [2.9–4.3] 3.3 [2.7–3.9] 0.002
LDL cholesterol, mmol/L 2.3 [1.8–2.9] 2.2 [1.8–2.8] 2.4 [1.9–3.0] 2.2 [1.8–2.8] 0.023
Triglycerides, mmol/L 1.5 [1.1–2.1] 1.5 [1.1–2.2] 1.6 [1.1–2.3] 1.4 [1.0–1.9] 0.060
Albumine:creatinine ratio, mg/mmol 0.8 [0.4–1.5] 0.8 [0.4–1.5] 1.0 [0.4–1.5] 0.6 [0.2–1.4] 0.104
Medication
Dietary measures only, n (%) 182 (19.2) 69 (21.9) 67 (21.3) 47 (14.8) 0.042
Oral blood glucose lowering drugs, n (%) 741 (78.3) 228 (73.5) 245 (77.8) 265 (83.3) 0.012
Metformin, n (%) 707 (74.7) 217 (70.0) 230 (73.0) 257 (80.8) 0.006
Sulfonylurea derivatives, n (%) 261 (27.6) 84 (27.1) 86 (27.3) 91 (28.6) 0.899
Thiazolinediones, n (%) 10 (1.1) 4 (1.3) 5 (1.6) 1 (0.3) 0.263
DDP4 inhibitors, n (%) 35 (3.7) 10 (3.2) 16 (5.1) 9 (2.8) 0.281
Insulin, n (%) 123 (13.0) 40 (12.9) 35 (11.1) 48 (15.1) 0.331
Antihypertensive drugs, n (%) 799 (84.5) 270 (87.7) 269 (85.4) 258 (81.1) 0.070
Diuretics, n (%) 349 (36.9) 125 (40.3) 112 (35.6) 112 (35.2) 0.207
Beta blockers, n (%) 354 (37.4) 111 (35.8) 131 (41.6) 111 (34.9) 0.182
Calcium antagonists, n (%) 170 (18.0) 60 (19.4) 54 (17.1) 56 (17.6) 0.657
RAAS blockers, n (%) 514 (54.3) 170 (54.8) 170 (54.0) 174 (54.7) 0.855
Cholesterol lowering drugs, n (%) 752 (79.5) 248 (80.0) 242 (76.8) 260 (81.8) 0.288
Antidepressive drugs, n (%) 44 (4.7) 12 (3.9) 19 (6.0) 13 (4.1) 0.375
Thrombocyte aggregation inhibitors, n (%) 168 (17.8) 47 (15.2) 59 (18.7) 62 (19.5) 0.340
Data are presented as number (%), mean (SD) or median [IQR]. Significant (p < 0.05) values are emphasized in bold. HbA1c is expressed in both IFCC derived
mmol/mol as DCCT derived %. Missing values: gender n= 2, HbA1c n= 4, total cholesterol n=4, HDL-cholesterol n=5, smoking n= 7. eGFR-MDRD n=7,
systolic blood pressue n= 11. Abbreviations: BMI, body mass index; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; CABG,
coronary artery bypass grafting; TIA, transient ischemic attack; CVA, cerebral vascular event; HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration
rate; HDL, high-density lipoprotein; LDL, high-density lipoprotein; DDP4, dipeptidyl peptidase 4; RAAS, renin-angiotensin-aldosterone system; R-SH total, free thiol
groups.
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mediated damage in the progression of T2DM and associated compli-
cations, we aimed to investigate the association between circulating
free thiols and T2DM in a large cohort of stable patients.
Subjects, materials and methods
This is a prospective, observational cohort study. Baseline data and
blood samples were obtained from the e-VitaDM study, which was
designed to assess the feasibility of using an online platform in routine
primary healthcare for subjects with T2DM. As a pre-specified part of
the e-VitaDM study, patients were assessed in a long-term follow-up.
This prospective arm was nested within the Zwolle Outpatient Diabetes
project Integrating Available Care (ZODIAC) study. Both the e-VitaDM
and the ZODIAC study are described in detail elsewhere [17]. The
primary aim of the present study was to investigate the association
between baseline serum concentrations of R-SH with indices of T2DM
management, in particular HbA1c. A secondary, hypothesis-generating
aim was to analyse the longitudinal relationship between baseline R-SH
concentrations and the risk of death and/or complications (both micro-
and macrovascular).
This study was conducted in general practices that are connected to
the Care Group Drenthe in the Drenthe-region (located in the North-
East) of the Netherlands. Fifty-two out of the 110 general practices in
this care group agreed to participate. In these practices, approximately
8300 patients with T2DM were treated between 2012 and 2014.
Patients were recruited during a regular check-up by their practice
nurse and included from May 2012 until September 2014 [17,18].
Patients with T2DM, aged ≥18 years and the general practitioner as
main care provider for T2DM were eligible for participation [17]. For
the e-VitaDM study there were no exclusion criteria. A total of 1710 out
of 3988 patients, who were asked to participate in the eVita-DM study,
gave written informed consent. Of these patients, 764 were not in-
cluded in the present study due to the inability to match blood samples
taken in the e-VitaDM with the clinical data from the ZODIAC study. A
further 3 individuals were excluded from the final analysis because
apparent R-SH concentrations were below the detection limit. Conse-
quently, the final study cohort consisted of 943 patients.
Baseline demographic data included gender, age, duration of dia-
betes, BMI, alcohol intake and smoking habits. Information concerning
alcohol intake and smoking habits was derived from questionnaires at
baseline. Medical data were extracted from the diabetes-specific data-
base at the Diabetes Centre of the Isala hospital (Zwolle, The
Netherlands). This centre gathers data of primary care-treated patients
with T2DM in a large part of the Netherlands on an annual basis, to
Fig. 1. Histogram of serum R-SH concentrations in type 2 diabetes.
Table 2
Univariable and multivariable associations of serum R-SH concentrations with
clinical parameters in type 2 diabetes.
Univariable Multivariable
St. Beta P-value St. Beta P-value Part
correlation
Demographics
Age, years −0.176 <0.001 −0.190 <0.001 −0.148
Diabetes duration, years 0.012 0.355 0.115 0.006 0.098
Male gender (male= 1) −0.162 <0.001 0.219 <0.001 0.138
Current smoker −0.012 0.363 −0.060 0.119 −0.056
BMI, kg/m2 −0.171 <0.001 −0.164 <0.001 −0.149
Systolic blood pressure,
mm Hg
−0.051 <0.001 0.016 0.714 0.013
Diastolic blood
pressure, mm Hg




−0.070 <0.001 −0.088 0.282 −0.039
Micro-albuminuria 0.000 0.986 0.046 0.499 0.024
Macro-albuminuria −0.064 <0.001 0.080 0.298 0.037
Retinopathy −0.091 <0.001 −0.035 0.490 −0.027
Neuropathy −0.065 <0.001 −0.024 0.685 −0.015
Macrovascular
complications
−0.054 <0.001 −0.127 0.024 −0.081
Angina pectoris 0.001 0.935 0.068 0.089 0.061
Myocardial infarction −0.057 <0.001 −0.013 0.791 0.009
PTCA −0.026 0.049 0.000 0.994 0.000
CABG −0.056 <0.001 −0.036 0.368 −0.032
TIA 0.055 < 0.001 0.068 0.086 0.062
CVA 0.048 <0.001 0.036 0.336 0.034
Heart failure −0.074 <0.001 −0.065 0.087 −0.061
Laboratory Measurements
HbA1c, mmol/mol −0.135 <0.001 −0.204 <0.001 −0.182
Creatinine , µmol/L −0.123 <0.001 −0.123 0.110 −0.057
eGFR (MDRD), ml/
min/1.73m2
0.036 0.007 0.097 0.167 0.050
Total cholesterol,
mmol/L
−0.030 0.025 0.226 0.279 0.039
Total cholesterol:HDL
ratio
−0.060 <0.001 −0.193 0.129 −0.054
HDL cholesterol, mmol/
L
0.022 0.102 −0.169 0.205 −0.045
LDL cholesterol, mmol/
L
−0.034 0.011 −0.073 0.584 −0.016
Triglycerides, mmol/L −0.055 <0.001 −0.018 0.810 −0.009
Albumin:creatinine
ratio, mg/mmol
−0.089 <0.001 −0.059 0.477 −0.025
Medication
Dietary measures only −0.064 <0.001 0.121 0.229 0.041
Oral blood glucose
lowering drugs
0.087 < 0.001 0.025 0.849 0.007
Metformin 0.104 < 0.001 0.125 0.155 0.049
Sulfonylurea
derivatives
0.026 0.053 0.019 0.632 0.017
Thiazolinediones −0.046 0.001 −0.044 0.230 −0.041
DDP4 inhibitors −0.002 0.872 −0.027 0.447 −0.026
Insulin −0.015 0.254 0.066 0.123 0.053
Antihypertensive drugs −0.075 <0.001 −0.051 0.232 −0.041
Diuretics −0.050 <0.001 −0.031 0.426 −0.027
Beta blockers −0.005 0.723 0.044 0.270 0.038
Calcium antagonists −0.035 0.011 −0.031 0.399 −0.029
RAAS blockers −0.012 0.367 0.043 0.295 0.036
Cholesterol lowering
drugs




0.044 0.001 0.137 0.001 0.116
Significant (p < 0.05) values are emphasized in bold. Abbreviations: BMI,
body mass index; MI, myocardial infarction; PTCA, percutaneous transluminal
coronary angioplasty; CABG, coronary artery bypass grafting; TIA, transient
ischemic attack; CVA, cerebral vascular event; HbA1c, glycated hemoglobin;
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL,
high-density lipoprotein; DDP4, dipeptidyl peptidase 4; RAAS, renin-angio-
tensin-aldosterone system; R-SH, total free thiol groups.
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provide benchmark information to general practitioners. This database
includes information on physical examination, use of medication, and
laboratory blood and urine tests. The following data were extracted:
date of diabetes diagnosis, height, weight, diastolic and systolic blood
pressure, cholesterol, HbA1c, estimated glomerular filtration rate
(eGFR) based on the modification of diet in renal disease (MDRD)
equation, urine creatinine, urine albumin, urine albumin:creatinine
ratio, and the presence of macrovascular- and microvascular compli-
cations.
Macrovascular complications were defined as (a history of) angina
pectoris (AP), myocardial infarction (MI), percutaneous transluminal
coronary angioplasty (PTCA), coronary artery bypass grafting (CABG),
cerebrovascular accident (CVA) or transient ischemic attack (TIA).
Microvascular complications were defined as diabetic retinopathy, al-
buminuria (both micro- and macroalbuminuria) and diabetic peripheral
neuropathy. Microalbuminuria was defined as 20–200mg/L albumin or
an albumin:creatinine ratio between 2.5 and 25mg/mmol in men and
3.5–35mg/mmol in women. Macro-albuminuria was defined as>
200mg/L albumin or a albumin:creatinine ratio greater than 25mg/
mmol and 35mg/mmol for men and women, respectively [19]. An
ophthalmologist determined the presence of diabetic retinopathy
biannually. Foot sensibility was tested with 5.07 Semmes-Weinstein
monofilaments. Neuropathy was defined as two or more errors in a test
of three, affecting at least one foot. Blood glucose-lowering therapy was
categorized into: dietary measures only, oral blood glucose lowering
drugs (OBGLDs) including metformin, sulfonylurea derivatives, thia-
zolidinediones and DDP4 inhibitors, and insulin therapy. HbA1c is ex-
pressed in both derived NGSP units (as %) and IFCC-recommended (as
mmol/mol) units.
Patients were instructed to be in a fasted state when the blood
samples were collected. Venous blood samples were collected into BD
Vacutainer™ serum tubes, centrifuged and the serum was stored directly
in aliquots at −80 °C until measurement. R-SH were detected in serum
aliquots not subjected to any prior freeze/thaw cycle as previously
described, with minor modifications [20,21]. Briefly, 75 µl serum was
diluted 1:4 in 0.1M Tris buffer (pH 8.2) and then transferred to a 96-
well plate. Using a Sunrise microplate reader (Tecan Trading AG,
Männedorf, Switzerland), background absorption was measured at
412 nm with a reference filter at 630 nm. Subsequently, 10 µl 3.8mM
5,5′ -dithio-bis (2-nitrobenzoic acid) (DTNB; Sigma Aldrich, Zwijn-
drecht, Netherlands) in 0.1M phosphate buffer (pH 7) was added to the
samples. Following 20min of incubation at room temperature, ab-
sorption was read again. The concentration of R-SH in the samples was
determined by comparing their absorbance readings to a standard curve
of L-cysteine (15–1000 µM; Fluka Biochemika, Buchs, Switzerland) in
0.1M Tris and 10mM EDTA (pH 8.2). Measurements were performed in
January 2017 at the department of pathology and medical biology of
the university medical centre Groningen (The Netherlands).
Statistical analyses were performed using SPSS (IBM SPSS Statistics
for Windows, Version 23.0. Armonk, NY: IBM Corp.) and STATA ver-
sion 15 (StataCorp. 2015. Stata Statistical Software: Release 15. College
Station, TX: StataCorp LP.). Multiple imputations were used for missing
data on the independent variables, assuming data was missing (com-
pletely) at random. Five imputed datasets were created and the pooled
results are described. The distributions of all variables were examined
using histograms and Q-Q plots. Results were expressed as mean (with
standard deviation (± SD)) or median (with interquartile range [IQR])
for normally distributed and non-normally distributed data, respec-
tively. Nominal data are presented as n (with percentage (%)). A sig-
nificance level of 5% (two-sided) was used. The study population was
subdivided into tertiles based on the concentrations of serum R-SH to
visualize associations between R-SH and clinical parameters.
Differences in baseline characteristics between the groups were ana-
lysed using one-way ANOVA for normally distributed continuous data,
the Kruskal-Wallis test for non-normally distributed continuous data
and the Chi-Square test for nominal data. Linear regression was used to
test the association between R-SH concentrations and individual para-
meters. For the hypothesis generating part we performed Cox regression
analyses to assess the risk of death and complications (both micro- and
macrovascular), microvascular complications or macrovascular com-
plications during follow-up. Four models were used: (1) a crude model,
(2) a model that included age, gender and R-SH, (3) a fully adjusted
(duration of diabetes, smoking (yes/no), BMI, systolic blood pressure,
HbA1c, log serum creatinine, cholesterol-HDL ratio, use of OBGLD and
use of insulin) model in which R-SH was included, and (4) the fully
adjusted model without R-SH. There are no data regarding variables
influencing R-SH concentrations in T2DM; we therefore chose the
variables in the current models based on their known influence on
complications in T2DM. Proportional-hazards assumption were con-
firmed by Stata’s PH-test. The Harrel’s C and R2 statistics were used to
investigate the capability of each model to predict mortality [22]. The
Table 3
Hazard ratio’s and additional value of baseline R-SH concentrations in risk prediction compared to established cardiovascular risk markers.
Model 1 Model 2 Model 3 Model 4
Any complication and death
Hazard ratio (95%CI) 0.994 (0.991, 0.996) 0.993 (0.990, 0.996) 0.994 (0.991, 0.996) NA
Harrell’s C (95% CI) 0.58 (0.54, 0.63) 0.60 (0.56, 0.64) 0.62 (0.58, 0.66) 0.58 (0.54, 0.63)
R2 0.05 (0.02, 0.11) 0.06 (0.03, 0.13) 0.06 (0.03, 0.15) 0.01 (0.02, 0.09)
Grønnesby and Borgan test p-value 0.45 0.58 0.41 0.58
Macrovascular
Hazard ratio (95%CI) 0.994 (0.991, 0.997) 0.992 (0.985, 0.998) 0.993 (0.986, 0.999) NA
Harrell’s C (95% CI) 0.62 (0.53, 0.71) 0.63 (0.54, 0.72) 0.68 (0.61, 0.76) 0.67 (0.58, 0.75)
R2 0.09 (0.00, 0.26) 0.09 (0.00, 0.29) 0.02 (−0.01, 0.32) 0.03 (−0.02, 0.26)
Grønnesby and Borgan test p-value 0.46 0.60 0.14 0.66
Microvascular
Hazard ratio (95%CI) 0.994 (0.991, 0.997) 0.994 (0.991, 0.997) 0.993 (0.990, 0.996) NA
Harrell’s C (95% CI) 0.57 (0.53, 0.63) 0.61 (0.57, 0.65) 0.63 (0.58, 0.67) 0.59 (0.55, 0.64)
R2 0.04 (0.01, 0.1) 0.06 (0.03, 0.12) 0.06 (0.03, 0.17) 0.01 (0.00, 0.11)
Grønnesby and Borgan test p-value 0.41 0.92 0.49 0.25
Model 1: crude.
Model 2: as model 1 and also adjusted for age and sex.
Model 3: as model 2 and also adjusted for duration of diabetes, smoking (yes/no), BMI, SBP, HbA1c, log serum creatinine , cholesterol-HDL ratio, use of blood glucose
lowering drugs (yes/no), use of insulin (yes/no), and R-SH.
Model 4: as model 3 without R-SH.
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Harrel’s C statistic ranges from 0 to 1, with 1 indicating a perfect pre-
diction capacity of the model. Calibration, a measure to evaluate how
well predicted probabilities agree with observed risks, was assessed
using the Grønnesby and Borgan ‘goodness-of-fit’ likelihood-ratio test, a
non-significant result means an acceptable calibration [23].
The study protocol was registered prior to the start of the study
(study ID METC 11.10117) and approved by the Medical Ethical
Committee of the Isala hospital. The protocol was also registered on
clinicaltrials.gov (study ID NCT01570140). All patients gave written
informed consent.
Results
Baseline characteristics of the 943 patients with T2DM are pre-
sented in Table 1. The patient cohort had a mean age of 65 (± 10)
years, 55% were male, diabetes duration was 6.5 [2.9–10.1] years and
HbA1c concentration was 6.7 ± 0.7% (50 (± 9) mmol/mol). At
baseline, 29.2% of patients had a microvascular complication: 18.5%
had neuropathy, 4.0% retinopathy, 12.4% microalbuminuria and 1.3%
had macroalbuminuria. Twenty-three per cent of patients had a history
of macrovascular complications. Considering treatment, 19% of pa-
tients were treated with dietary measures alone, while 78% received
OBGLD and 13% (also) received insulin therapy. Antihypertensive or
lipid lowering medication was prescribed to 85% and 80% of patients
respectively, while 18% used thrombocyte aggregation inhibitors. All
patients with macrovascular complications used platelet aggregation
inhibitors.
Among all patients, R-SH concentrations were normally distributed,
with a mean concentration of 203 [170–239] μM (see Fig. 1). Con-
centrations of R-SH were significantly higher in men: 210 (± 47)
versus 194 (± 47) μM in women, respectively (P < 0.001). When
comparing the different tertiles of R-SH, patients within the highest
tertile (R-SH concentration of> 227 μM) were significantly younger,
more frequently male, had a lower BMI, less microvascular complica-
tions, a lower HbA1c, and a more favourable lipid profile. Moreover,
these individuals were more often treated with diet alone or metformin
as compared to those in the other tertiles. According to the multivariate
model (see Table 2), the presence of macrovascular complications was
inversely related to concentrations of R-SH. In addition, for each unit
increase in age (year), BMI (kg/m2), diastolic blood pressure (mmHg)
and HbA1c (mmol/mol) the concentrations of R-SH decreased. Male
gender, diabetes duration (per year) and the use of platelet aggregation
inhibitors were positively associated with R-SH concentration.
During the follow-up period of 1.2 [0.4–1.5] years, 3 (0.3%) pa-
tients died and there were 212 (22.4%) new microvascular and 51
(5.4%) macrovascular complications. Sixty-three patients (6.7%) de-
veloped neuropathy, 20 (2.1%) retinopathy, 118 (12.5%) micro-albu-
minuria and 33 (3.5%) macro-albuminuria. Thirty-nine (4.1%) of the
patients developed angina pectoris, 1 (0.1%) myocardial infarction, 1
(0.1%) CVA, 4 (0.4%) TIA and 5 (0.5%) heart failure. One (0.1%) pa-
tient underwent a CABG and 5 patients (0.5%) a PTCA.
As presented in Table 3, the age- and sex adjusted hazard ratios
(HRs) for developing microvascular, macrovascular or any complica-
tion plus death were 0.994 (95% CI 0.991, 0.997) in the lowest tertile,
0.992 (95% CI 0.985, 0.998) and 0.993 (95% CI 0.990, 0.996) in
middle and highest tertile, respectively. After adjustment for potential
confounders these HRs remained stable. There was no relevant differ-
ence in the Harrell's C statistics to predict macrovascular complications
in the models with or without R-SH: 0.68 (95%CI 0.61, 0.76) and 0.67
(95%CI 0.58, 0.75). The Harrell’s C statistics to predict microvascular
complications or any complication plus death were 0.63 (95% CI 0.58,
0.67) and 0.62 (95% CI 0.58, 0.66) in the models with R-SH and 0.59
(95% CI 0.55, 0.64) and 0.58 (95% CI 0.54, 0.63) without R-SH.
Discussion
Serum free thiols, a measure of systemic redox status, are associated
with HbA1c and micro- and macrovascular complications in outpatients
with T2DM. Patients with higher concentrations of free thiols had
better glycemic control as compared to patients with lower con-
centrations. Nevertheless, the additional value of R-SH for risk predic-
tion of long-term complications was very modest during the short-term
follow-up of this study. To the best of our knowledge, these data are the
first to connect total serum R-SH status with clinical parameters and
outcomes in a large T2DM cohort.
In this study we measured total R-SH concentrations to test the
hypothesis that protein R-SH availability in human serum from T2DM
patients is a relatively simple integrative marker of systemic redox
status, and thereby disease status in T2DM. R-SH may serve as an im-
portant buffer for ROS and may thereby contribute to protection against
the detrimental effects of reduced insulin signalling [2]. Indeed, our
data demonstrate that higher concentrations of R-SH were associated
with better glycemic control. The multivariable analysis revealed a
strong correlation between serum R-SH and male gender. This gender
difference may be related to differences in physical activity and/or
muscle mass and the subsequent need for a greater buffer capacity to
detoxify exercise-related free radical formation. Nevertheless, the
nature of this needs to be explored in the future but is in line with our
findings in a cohort of renal transplant recipients (n= 707) in which
males also had higher serum R-SH concentrations [13]. Interestingly,
diabetes duration was also positively association with levels of R-SH.
This finding seems contra-intuitive since (increasing) diabetes duration
is a well-known risk factor for the development of complications. Al-
though speculative, it could be hypothesized that the diabetes duration
of the present population (median of 6.5 years) distorted the relation
with R-SH: with a high proportion of participants having a short dia-
betes duration, short treatment duration, suboptimal glycemic control
and consequent low R-SH concentrations.
We observed that baseline serum R-SH concentrations were in-
versely associated with complications. This raises the question whether
R-SH might be a promising therapeutic target. In renal transplant re-
cipients we found that higher circulating R-SH concentrations were
associated with a significantly lower future risk of premature death and
graft failure [13]. This makes free R-SH measurements a potentially
interesting and inexpensive screening tool for the early detection of a
‘high risk’ profile for future development of graft failure. The current
data, however, does not support use of R-SH measurements for risk
prediction in T2DM at present: there was only a very modest increase in
predictive power of our model when adding R-SH to the model with
known cardiovascular risk factors. However, the short follow-up dura-
tion of this study may well have influenced this finding. This may also
be emphasized by the already low Harrell’s C statistics (of 0.59–0.67) in
the models with known (long-term) cardiovascular risk factors and
without R-SH. Therefore, studies with longer follow-up duration are
warranted.
In addition to the limited follow-up duration our study has other
limitations. For 45% of patients we were unable to match blood samples
with clinical data. Our cohort is from a single region and comprises
predominantly (98.8%) Caucasians: this limits the generalization of our
data. Furthermore, this study lacks data on other plasma antioxidant
species such as ascorbate, uric acid and small-molecular-weight thiols,
markers of inflammation, glucose and insulin concentrations. Particular
strengths of the study include the large cohort size, a considerable di-
versity in vintage of the duration and severity of the disease and the
characterization of our patients.
Taken together, these data are the first to link total serum R-SH
status to clinical parameters, including HbA1c, and outcomes in a large
cohort of patients with T2DM. High serum R-SH concentrations seem to
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correlate with a better disease profile. However, the additional value of
R-SH for risk prediction of complications was not relevant during the
short-term follow-up in the present study. Further studies are warranted
to explore the potential of R-SH as a modifiable marker for whole-body





Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jcte.2019.100182.
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